Hydroxychloroquine (HCQ) — Competitive Intelligence Brief

Hydroxychloroquine (HCQ) (Hydroxychloroquine (HCQ)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial immunomodulator. Area: Immunology, Rheumatology.

phase 3 Antimalarial immunomodulator TLR7, TLR9, and lysosomal pH-dependent pathways Immunology, Rheumatology Small molecule

Target snapshot

Hydroxychloroquine (HCQ) (Hydroxychloroquine (HCQ)) — Post Graduate Institute of Medical Education and Research, Chandigarh. Hydroxychloroquine is a quinoline antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine (HCQ) TARGET	Hydroxychloroquine (HCQ)	Post Graduate Institute of Medical Education and Research, Chandigarh	phase 3	Antimalarial immunomodulator	TLR7, TLR9, and lysosomal pH-dependent pathways
Single Dose of Hydroxychloroquine	Single Dose of Hydroxychloroquine	Shahid Beheshti University of Medical Sciences	marketed	Antimalarial immunomodulator	Toll-like receptors (TLR); lysosomal pH modulation
Hydroxychloroquine reduced	Hydroxychloroquine reduced	University of Sao Paulo General Hospital	marketed	Antimalarial immunomodulator	Lysosomal function; TLR signaling
Hydroxychloroquine Sulfate Loading Dose	Hydroxychloroquine Sulfate Loading Dose	Government of Punjab, Specialized Healthcare and Medical Education Department	marketed	Antimalarial immunomodulator	Toll-like receptors (TLR), lysosomal pH modulation
Group Hydroxychloroquine and apixaban	Group Hydroxychloroquine and apixaban	Universidade do Vale do Sapucai	phase 3	Combination therapy: antimalarial immunomodulator + anticoagulant	Hydroxychloroquine: lysosomal pH and immune signaling; Apixaban: Factor Xa
Hydroxychloroquine Oral Product	Hydroxychloroquine Oral Product	Hospital do Coracao	phase 3	Antimalarial immunomodulator	Toll-like receptors (TLR), lysosomal pH modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial immunomodulator class)

1. Government of Punjab, Specialized Healthcare and Medical Education Department · 1 drug in this class
2. Hospital do Coracao · 1 drug in this class
3. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
4. Shahid Beheshti University of Medical Sciences · 1 drug in this class
5. University of Sao Paulo General Hospital · 1 drug in this class